153 related articles for article (PubMed ID: 31079860)
1. Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies.
Liu Y; Qiu T; Liu Y; Wang J; Hu K; Bao F; Zhang C
Clin Ther; 2019 Jun; 41(6):1151-1163. PubMed ID: 31079860
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
3. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
4. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
Perreault S; McManus D; Anderson A; Lin T; Ruggero M; Topal JE
J Oncol Pharm Pract; 2019 Sep; 25(6):1305-1311. PubMed ID: 29996736
[TBL] [Abstract][Full Text] [Related]
5. Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: A population pharmacokinetic approach.
Tang D; Song BL; Yan M; Zou JJ; Zhang M; Zhou HY; Wang F; Xiao YW; Xu P; Zhang BK; Chen XJ; Xiang DX; Linh Banh H
Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):34-43. PubMed ID: 30715804
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
[TBL] [Abstract][Full Text] [Related]
7. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
[TBL] [Abstract][Full Text] [Related]
8. Dosage optimization of voriconazole in children with haematological malignancies based on population pharmacokinetics.
Wu Y; Lv C; Wu D; Qi J; Cai R; Zhou S; Li C; Wei Y; Liu T
J Clin Pharm Ther; 2022 Dec; 47(12):2245-2254. PubMed ID: 36345158
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Voriconazole and Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients With Liver Cirrhosis.
Ren QX; Li XG; Mu JS; Bi JF; Du CH; Wang YH; Zhu H; Lv P; Zhao QG
J Pharm Sci; 2019 Dec; 108(12):3923-3931. PubMed ID: 31562869
[TBL] [Abstract][Full Text] [Related]
10. Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases.
Khan-Asa B; Punyawudho B; Singkham N; Chaivichacharn P; Karoopongse E; Montakantikul P; Chayakulkeeree M
Antibiotics (Basel); 2020 Sep; 9(9):. PubMed ID: 32899425
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
[TBL] [Abstract][Full Text] [Related]
12. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
[TBL] [Abstract][Full Text] [Related]
13. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis.
Jiang Z; Wei Y; Huang W; Li B; Zhou S; Liao L; Li T; Liang T; Yu X; Li X; Zhou C; Cao C; Liu T
Front Pharmacol; 2022; 13():982981. PubMed ID: 36225581
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
Tang L; Yang XF; Qiao M; Zhang L; Tang XW; Qiu HY; Wu DP; Sun AN
J Mycol Med; 2018 Jun; 28(2):379-383. PubMed ID: 29673771
[TBL] [Abstract][Full Text] [Related]
18. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Voriconazole and Dose Optimization in Elderly Chinese Patients.
Wang J; Shen Y; Wu Z; Ge W
J Clin Pharmacol; 2024 Feb; 64(2):253-263. PubMed ID: 37766506
[TBL] [Abstract][Full Text] [Related]
20. Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization.
Zhang Y; Zhao S; Wang C; Zhou P; Zhai S
Front Pharmacol; 2021; 12():636097. PubMed ID: 33815119
[No Abstract] [Full Text] [Related]
[Next] [New Search]
